Latest Tax Incentives News

Cycliq Group Ltd reported a 21% decline in customer receipts for Q2 FY2026, offset by a solid net operating cash inflow and a strong Black Friday campaign that generated $1.3 million in gross revenue.

Rhythm Biosciences has begun commercialising its blood-based colorectal cancer test, ColoSTAT®, following key accreditations and validation. The company also secured a strategic partnership with NHS England and expanded its geneType™ platform globally.

Cambium Bio has strengthened its financial footing with a $0.6 million R&D tax refund and a $2.4 million strategic placement, setting the stage for pivotal Phase 3 clinical trials of its lead ophthalmology candidate.

AdAlta Limited has aligned its AdCella manufacturing strategy with new US FDA guidelines, made a significant milestone payment to Shanghai Cell Therapy Group, and secured an additional R&D tax rebate, marking key progress in its cellular immunotherapy pipeline.

Galan Lithium advances construction at its Hombre Muerto West project, targeting first lithium production in the first half of 2026, while strategically expanding its Greenbushes South tenure in Western Australia.

Genetic Signatures reported a $3.3 million quarterly revenue with growing international sales and a robust cash position, while preparing for a leadership change.

Cambium Bio has locked in a A$2.4 million strategic investment from Zheng Yang Biomedical Technology, reinforcing its push into pivotal Phase 3 trials for its dry eye disease treatment.

Orthocell has increased its investment in Marine Biomedical to 11.7%, securing exclusive distribution rights to the innovative PearlBone™ technology as it nears FDA approval.

Advanced Braking Technology Ltd reports a robust Q2 FY26 with a 34% increase in product sales revenue and a 191% jump in net profit before tax, underpinned by strong international expansion and domestic contract wins.

Recce Pharmaceuticals has received a $5.3 million R&D tax rebate from the Australian Taxation Office, providing a significant cash injection to support its innovative synthetic anti-infective drug development programs.

Great Dirt Resources has confirmed high-grade manganese mineralisation in NSW and identified 24 new exploration targets through advanced R&D techniques, supported by a $315k tax rebate and a strong cash position.

Elixir Energy has begun mobilising a drilling rig for the Lorelle-3 appraisal well in Queensland’s Taroom Trough, aiming to unlock commercial gas flows by mid-2026.